Relieves inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. ANDA 205620, held by Zydus Lifesciences. Desoximetasone.
As of Nov 15, 2026, ANDA 205620 (Desoximetasone), held by Zydus Lifesciences, was first approved by FDA on Sep 28, 2018, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Desoximetasone cream, 0.25% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 28, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Desoximetasone0.25% · cream;topical | Desoximetasone | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
